1μg (R: reducing condition).
Product Details
Product Details
Product Specification
Species | Rat |
Synonyms | Txgp1; OX40L receptor; ACT35 |
Accession | P15725 |
Amino Acid Sequence | Val20-Pro210 with Human IgG1 Fc at C-Terminus |
Expression System | HEK293 |
Molecular Weight | 60-80kDa (Reducing) |
Purity | > 95% by SDS-PAGE |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | Human IgG1 Fc |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, PH7.4, 5% trehalose |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
Reference | 1. Cancer Res. Roles of OX40 in the pathogenesis and the control of diseases.Int J Hematol . 2006 Jan;83(1):17-22. Toshiyuki Hori. |
Background
OX40, a member of the tumor necrosis factor receptor superfamily, is selectively expressed on activated T-cells. The engagement of OX40 during interactions between T-cells and dendritic cells is essential for the clonal expansion of antigen-specific T-cells and the establishment of T-cell memory. Recent animal model studies have highlighted the significant role of OX40 in the development of immunologic abnormalities, including inflammatory, autoimmune, infectious, allergic, and allotransplantation-related diseases. Inhibition of the OX40-OX40L interaction has demonstrated potential in preventing, curing, or alleviating these conditions. Conversely, OX40 activation can disrupt tolerance in cancer, reactivating antitumor immunity. These insights underscore the OX40/OX40L system as a promising target for immunotherapeutic interventions in the treatment of these diseases.
Picture
Picture
SDS-PAGE
ELISA
Immobilized OX40 Ligand/TNFSF4 His Tag Protein, Mouse (Cat. No. UA011097) at 2.0μg/mL (100μL/well) can bind OX40/TNFRSF4/CD134 Fc Chimera Protein, Rat (Cat. No. UA010929) with EC50 of 3.98-4.88 ng/mL.
